Ascendis Pharma A/S (ASND) Competitors

Ascendis Pharma A/S (NASDAQ:ASND) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Is ASND or BNTX more profitable?

BioNTech has a net margin of -15.16% compared to Ascendis Pharma A/S's net margin of -130.33%. Ascendis Pharma A/S's return on equity of 0.00% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	-130.33%	N/A	-48.77%
BioNTech	-15.16%	-2.35%	-2.05%

Do analysts recommend ASND or BNTX?

Ascendis Pharma A/S currently has a consensus target price of $191.77, suggesting a potential upside of 54.18%. BioNTech has a consensus target price of $138.79, suggesting a potential upside of 35.88%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, equities analysts clearly believe Ascendis Pharma A/S is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.92
BioNTech	0 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.81

Do institutionals and insiders believe in ASND or BNTX?

15.5% of BioNTech shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the media prefer ASND or BNTX?

In the previous week, Ascendis Pharma A/S and Ascendis Pharma A/S both had 30 articles in the media. Ascendis Pharma A/S's average media sentiment score of 0.42 beat BioNTech's score of 0.31 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	10 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	5 Very Positive mention(s)	4 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has higher valuation & earnings, ASND or BNTX?

BioNTech has higher revenue and earnings than Ascendis Pharma A/S. BioNTech is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$288.08M	26.18	-$521.07M	-$8.08	-15.39
BioNTech	$3.04B	8.05	$1.01B	-$2.10	-48.64

Which has more risk & volatility, ASND or BNTX?

Ascendis Pharma A/S has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500.

Does the MarketBeat Community believe in ASND or BNTX?

Ascendis Pharma A/S received 303 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 66.52% of users gave Ascendis Pharma A/S an outperform vote while only 45.48% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
Ascendis Pharma A/S	Outperform Votes 439 66.52%	Underperform Votes 221 33.48%
BioNTech	Outperform Votes 136 45.48%	Underperform Votes 163 54.52%

Summary

Ascendis Pharma A/S beats BioNTech on 11 of the 18 factors compared between the two stocks.